Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease
- PMID: 30626715
- PMCID: PMC6342564
- DOI: 10.1126/scitranslmed.aau6550
Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease
Erratum in
-
Erratum for the Research Article: "Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease" by B. P. Lucey, A. McCullough, E. C. Landsness, C. D. Toedebusch, J. S. McLeland, A. M. Zaza, A. M. Fagan, L. McCue, C. Xiong, J. C. Morris, T. L. S. Benzinger, D. M. Holtzman.Sci Transl Med. 2020 Jan 8;12(525):eaba5187. doi: 10.1126/scitranslmed.aba5187. Sci Transl Med. 2020. PMID: 31915302 No abstract available.
Abstract
In Alzheimer's disease (AD), deposition of insoluble amyloid-β (Aβ) is followed by intracellular aggregation of tau in the neocortex and subsequent neuronal cell loss, synaptic loss, brain atrophy, and cognitive impairment. By the time even the earliest clinical symptoms are detectable, Aβ accumulation is close to reaching its peak and neocortical tau pathology is frequently already present. The period in which AD pathology is accumulating in the absence of cognitive symptoms represents a clinically relevant time window for therapeutic intervention. Sleep is increasingly recognized as a potential marker for AD pathology and future risk of cognitive impairment. Previous studies in animal models and humans have associated decreased non-rapid eye movement (NREM) sleep slow wave activity (SWA) with Aβ deposition. In this study, we analyzed cognitive performance, brain imaging, and cerebrospinal fluid (CSF) AD biomarkers in participants enrolled in longitudinal studies of aging. In addition, we monitored their sleep using a single-channel electroencephalography (EEG) device worn on the forehead. After adjusting for multiple covariates such as age and sex, we found that NREM SWA showed an inverse relationship with AD pathology, particularly tauopathy, and that this association was most evident at the lowest frequencies of NREM SWA. Given that our study participants were predominantly cognitively normal, this suggested that changes in NREM SWA, especially at 1 to 2 Hz, might be able to discriminate tau pathology and cognitive impairment either before or at the earliest stages of symptomatic AD.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Conflict of interest statement
Competing interests:
BPL, AM, ECL, CDT, JSM, AMZ, LM, and CX: No competing interests.
Figures
Comment in
-
Decreased NREM sleep linked with tauopathy.Nat Rev Neurol. 2019 Mar;15(3):126-127. doi: 10.1038/s41582-019-0140-1. Nat Rev Neurol. 2019. PMID: 30700823 No abstract available.
Similar articles
-
NREM sleep as a novel protective cognitive reserve factor in the face of Alzheimer's disease pathology.BMC Med. 2023 May 3;21(1):156. doi: 10.1186/s12916-023-02811-z. BMC Med. 2023. PMID: 37138290 Free PMC article.
-
Subthreshold Amyloid Predicts Tau Deposition in Aging.J Neurosci. 2018 May 9;38(19):4482-4489. doi: 10.1523/JNEUROSCI.0485-18.2018. Epub 2018 Apr 23. J Neurosci. 2018. PMID: 29686045 Free PMC article.
-
Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors.Neuropsychopharmacology. 2020 Jan;45(1):104-120. doi: 10.1038/s41386-019-0478-5. Epub 2019 Aug 13. Neuropsychopharmacology. 2020. PMID: 31408876 Free PMC article. Review.
-
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334. Brain. 2017. PMID: 28077397 Free PMC article.
-
Slow Wave Sleep Is a Promising Intervention Target for Alzheimer's Disease.Front Neurosci. 2020 Jun 30;14:705. doi: 10.3389/fnins.2020.00705. eCollection 2020. Front Neurosci. 2020. PMID: 32714142 Free PMC article. Review.
Cited by
-
Propofol enhancement of slow wave sleep to target the nexus of geriatric depression and cognitive dysfunction: protocol for a phase I open label trial.BMJ Open. 2024 May 30;14(5):e087516. doi: 10.1136/bmjopen-2024-087516. BMJ Open. 2024. PMID: 38816055 Free PMC article.
-
The association between sleep duration, bedtime, and cognitive ability in Chinese adults: Evidence from the China family panel studies.Heliyon. 2024 Apr 22;10(9):e30009. doi: 10.1016/j.heliyon.2024.e30009. eCollection 2024 May 15. Heliyon. 2024. PMID: 38737242 Free PMC article.
-
Midpoint of sleep is associated with sleep quality in older adults with and without symptomatic Alzheimer's disease.Sleep Adv. 2024 Apr 15;5(1):zpae023. doi: 10.1093/sleepadvances/zpae023. eCollection 2024. Sleep Adv. 2024. PMID: 38711547 Free PMC article.
-
Suboptimal self-reported sleep efficiency and duration are associated with faster accumulation of brain amyloid beta in cognitively unimpaired older adults.Alzheimers Dement (Amst). 2024 Apr 22;16(2):e12579. doi: 10.1002/dad2.12579. eCollection 2024 Apr-Jun. Alzheimers Dement (Amst). 2024. PMID: 38651160 Free PMC article.
-
Serotonergic dysfunction may mediate the relationship between alcohol consumption and Alzheimer's disease.Pharmacol Res. 2024 May;203:107171. doi: 10.1016/j.phrs.2024.107171. Epub 2024 Apr 9. Pharmacol Res. 2024. PMID: 38599469 Free PMC article. Review.
References
-
- Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367, 795–804 (2012). - PMC - PubMed
-
- Morris JC, Price JL, Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer’s disease. J Molec Neurosci 17, 101–118 (2001). - PubMed
-
- Fagan AM, Mintun MA, Mach RH, Lee S-Y, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM, Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Amyloid-beta-42 in humans. Ann Neurol 59, 512–519 (2006). - PubMed
-
- Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM, Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64, 343–349 (2007). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 AG032438/AG/NIA NIH HHS/United States
- P01 NS074969/NS/NINDS NIH HHS/United States
- P01 AG026276/AG/NIA NIH HHS/United States
- R01 AG054567/AG/NIA NIH HHS/United States
- P30 CA091842/CA/NCI NIH HHS/United States
- R01 AG052550/AG/NIA NIH HHS/United States
- K76 AG054863/AG/NIA NIH HHS/United States
- UL1 TR002345/TR/NCATS NIH HHS/United States
- RF1 AG053550/AG/NIA NIH HHS/United States
- P01 AG003991/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- R01 EB009352/EB/NIBIB NIH HHS/United States
- P30 NS098577/NS/NINDS NIH HHS/United States
- KL2 TR002346/TR/NCATS NIH HHS/United States
- UL1 TR000448/TR/NCATS NIH HHS/United States
- T32 EB021955/EB/NIBIB NIH HHS/United States
- KL2 TR000450/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical